Probiotic Topical Formulations for Skin Pathogen Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pathogenic microorganism infections, such as those caused by Malassezia and Trichophyton, are often ineffective, toxic, and prone to resistance, necessitating an alternative approach for treating skin diseases and conditions associated with these pathogens.
Innovation Solution
The use of pharmaceutical compositions comprising probiotics like Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus, and Janthinobacterium lividum, either isolated from human skin or synthetic, along with cryoprotectants like trehalose, to create stable and effective topical formulations for treating skin infections by inhibiting pathogenic microorganisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antifungal treatments are used to treat pathogenic microorganism infections, then infection symptoms may be temporarily suppressed, but treatment effectiveness is reduced due to resistance development and toxicity
Solution Approach 1:
The patent utilizes the probiotic bacteria's natural metabolic activities and competitive exclusion mechanisms to combat pathogenic microorganisms. The probiotics convert the harmful presence of pathogens into a beneficial situation by establishing a protective microbial ecosystem that naturally suppresses pathogen growth through resource competition and production of antimicrobial substances, thereby avoiding toxicity and resistance issues associated with conventional antifungals
Solution Approach 2:
The patent introduces probiotic bacteria as intermediary organisms that mediate the treatment process. These probiotics serve as living mediators that directly compete with and inhibit pathogenic microorganisms through their metabolic activities and production of antimicrobial compounds, providing an indirect but effective treatment mechanism that bypasses the limitations of direct antifungal agents
2Reliability
If probiotics are applied topically to treat skin infections, then pathogenic microorganisms are inhibited, but probiotic stability and viability on skin surface are challenged
Solution Approach 1:
The patent employs preliminary action by formulating probiotics with protective carriers and prebiotic substances before application to the skin. The formulation is designed in advance to protect probiotic viability during storage and application, ensuring the probiotics remain stable and viable when they contact the skin surface, thereby maintaining their antimicrobial efficacy
Solution Approach 2:
The patent utilizes parameter changes by optimizing formulation conditions such as pH, moisture content, and temperature to enhance probiotic stability. The formulation parameters are carefully controlled and adjusted to create an environment that maintains probiotic viability while preserving their antimicrobial activity against pathogenic microorganisms
Data Source
AI summary
Among other things, disclosed herein are compositions and methods for using human-isolated or synthetic Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus, Bacillus subtilis, or Janthinobacterium lividum. Compositions may improve skin health. Methods may include applying human-isolated or synthetic Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus, Bacillus subtilis, or Janthinobacterium lividum over a host or host area, such as skin or mucosa to minimize the presence of one or more pathogenic microbes, maximize therapeutic effects of one or more additional therapeutics, and/or improve health of a host or host area. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-isolated or synthetic Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus, Bacillus subtilis, or Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic or another microbe to maximize growth and/or metabolites (e.g., resulting from growth of a probiotic). Compositions and methods may include human-isolated or synthetic Alcaligenes faecalis, Bacillus altitudinis, Bacillus pumilus, Bacillus subtilis, or Janthinobacterium lividum metabolites.